Navigation Links
Open access to large-scale drug discovery data

The Wellcome Trust has awarded 4.7 million (5.8 million) to EMBL's European Bioinformatics Institute (EMBL-EBI) to support the transfer of a large collection of information on the properties and activities of drugs and a large set of drug-like small molecules from publicly listed company Galapagos NV to the public domain. It will be incorporated into the EMBL-EBI's collection of open-access data resources for biomedical research and will be maintained by a newly established team of scientists at the EMBL-EBI. These data lie at the heart of translating information from the human genome into successful new drugs in the clinic.

The human genome sequence provided a molecular 'parts list' for a human being, comprising all the genes and proteins that are encoded by our genetic blueprint. But to develop new medicines, it is important to catalogue how each of these 'parts' interacts with drugs and drug-like molecules. This interface of the genome with chemistry is a core part of the new scientific area of chemogenomics. For the past eight years, researchers at BioFocus DPI, the service division of Galapagos, have been integrating the existing collections of information in these two areas to develop a set of well-structured chemogenomic databases that can be used to help determine whether a particular molecule has the right properties to make an effective drug. BioFocus DPI licensed this information to pharmaceutical and biotech companies worldwide. As part of the Wellcome Trust grant announced today, the EBI will obtain the rights to the databases from BioFocus DPI. The award will make it possible to provide free access to this information for all researchers. "The scientific community worldwide will greatly benefit from unrestricted access to these data. It will aid their efforts in predictive drug discovery," says Galapagos CEO Onno van de Stolpe. "Galapagos has successfully accelerated its research programmes with these, and BioFocus DPI used the data to deliver on its contracts with customers. After this transfer, which we hope will contribute to the advancement of drug discovery research by improving access to the data that we have collected, we will continue to use these resources."

The transfer will empower academia to participate in the first stages of drug discovery for all therapeutic areas, including major diseases of the developing world. In future it could also result in improved prediction of drug side-effects. "We are excited to be able to provide information that defines the effects of a large number of small molecules on the body, and link this to the proteins that these molecules interact with, as part of our mission to provide wide access to bioinformatics tools to promote scientific progress and disseminate cutting-edge technologies to industry," says EMBL-EBI Director Janet Thornton. "With this transfer, we aim to facilitate faster and better drug discovery. It speaks to the importance of this information for translational research that the Wellcome Trust has chosen to support this particular transfer with sufficient long-term funding."

This unprecedented transfer of pharmaceutical data resources from the private sector to the public domain will have the greatest impact on researchers in academia and in small companies on limited budgets. "The Wellcome Trust has a strong commitment to making vital research tools freely available to the academic research community," says Dr Alan Schafer, Head of Molecular and Physiological Sciences at theWellcome Trust. "Enabling these previously proprietary data to enter the public domain will allow researchers worldwide to make free use of knowledge essential for drug discovery."


Contact: Cath Brooksbank
European Molecular Biology Laboratory

Related biology news :

1. Silicon Valley Technology Leaders LaserCard Corporation and Tesla Motors Sign LaserPass Secure Access Deal
2. Mandate for public access to NIH-funded research poised to become law
3. UK research community gets extended access to ScienceDirect
4. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
5. Easton, PA Police Officers Armed With BIO-key(R) Mobile Data Solution Access Information Anytime, Anywhere
6. SAGE and Hindawi announce landmark open access agreement
7. Top physics laboratories sign up to open access with PhysMath Central
8. Open-access tropical conservation journal launches
9. Excellence in open access research celebrated at BioMed Central awards dinner
10. New chlorine-tolerant, desalination membrane hopes to boost access to clean water
11. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
Post Your Comments:
(Date:10/8/2015)... SALT LAKE CITY , 8. Oktober ... (OTCQX: TRCK), ein global tätiges Unternehmen des ... man einem Vertrag mit der Gefängnisbehörde Virginias ... in dessen Rahmen elektronische Überwachungsdienste für alle ... Derek Cassell , Präsident für ...
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, ... today that it has signed a contract with the ... across the full range of sentences under the Department,s ... of the Americas. "This contract with the Virginia DOC ... the US and advances our position as a trusted ...
(Date:10/1/2015)... , Oct. 1, 2015  Biometrics includes diverse ... human body characteristics, such as fingerprints, eye retinas, ... Adoption of biometrics technology has been constantly increasing ... last five years. In addition to the most ... fingerprint recognition, other means of biometric authentication are ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... -- " Microbiology Culture Market - Global Industry ... " , the global microbiology culture market was valued ... bn by 2023, expanding at a CAGR of 5.9% during the ... Microbiology Culture Market - Global Industry Analysis, Size, Share, Growth, Trends, ... global microbiology culture market was valued at US$4.51 bn in 2014 ...
(Date:10/13/2015)... SAN DIEGO , Oct. 13, 2015 ... to collaborate in the development of a higher purity ... BASF under the Kolliphor ® P188 brand, is ... biological applications, such as a shear protectant in cell ... Mast,s lead product candidate. Under the agreement between BASF ...
(Date:10/13/2015)... Oct. 13, 2015  According to Kalorama Information, ... reach $102 billion by the end of 2015. ... health industry, as it is estimated that approximately ... laboratory tests. In addition to diagnosing patients, clinical ... disease progression, monitor drug treatment and conditions, and ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Clinovo recently ... expertise to the company’s fast growing clinical data solutions business. , Jeff Parr has ... companies of all sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name ...
Breaking Biology Technology: